Navigation Links
Bioenvision Shareholders Approve Acquisition by Genzyme Corporation

CAMBRIDGE, Mass., and NEW YORK, Oct. 22 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) and Bioenvision, Inc. (Nasdaq: BIVN) announced this afternoon that Bioenvision stockholders have voted to approve the acquisition of the company by Genzyme at a reconvened special shareholder meeting in New York. The transaction will be effective tomorrow. Bioenvision shares have now ceased trading and the company will be delisted from Nasdaq.

Fifty-six percent of Bioenvision's issued and outstanding shares of common stock and preferred stock, voting together as a single class on an as converted basis, supported the merger. This represents approximately 67 percent of the total shares voted.

With its acquisition of Bioenvision, Genzyme takes a significant step in enhancing its existing oncology business by gaining the exclusive, worldwide rights to clofarabine.

"We are very pleased that Bioenvision shareholders voted to support this merger," stated Mark J. Enyedy, president of Genzyme Oncology, a business unit of Genzyme Corporation. "We are deeply committed to furthering the clinical development of clofarabine and making it available on a global basis so that patients around the world with these very difficult forms of cancer will have access to the therapy. The successful completion of this acquisition creates the platform on which we will continue to build an international commercial presence for our oncology business."

Genzyme acquires Bioenvision in an all cash transaction valued at $5.60 per share, or approximately $345 million.

Christopher B. Wood, M.D., chairman and chief executive officer of Bioenvision, said, "We are pleased to conclude this merger process and we respect our shareholders' participation and opinions in this regard. We are confident in Genzyme's commitment to advance clofarabine, aided by their established clinical, regulatory and commercial infrastructure, and their already significant U.S. commercial experience with the compound."

Clofarabine is branded as Clolar(R) in the U.S. and Canada, where it is marketed by Genzyme for relapsed and refractory pediatric ALL patients. In Europe, Bioenvision and Genzyme co-developed clofarabine and Bioenvision currently markets the product under the brand name Evoltra(R), also for the treatment of relapsed and refractory pediatric ALL patients.

The companies have been developing clofarabine for significantly larger indications, including use as a first-line therapy for the treatment of adult acute myeloid leukemia (AML). Clofarabine has been granted orphan drug status for ALL and AML in both the United States and European Union.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,500 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was

selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including statements about the closing of acquisition of Bioenvision. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others: the possibility that the transaction is not completed; the possibility that certain closing conditions are not met, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R) and Clolar(R) are registered trademarks of Genzyme Corporation. Evoltra(R) is a registered trademark of Bioenvision, Inc. All rights reserved.

Genzyme's press releases and other company information are available at and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.


For Genzyme For Bioenvision

Catherine E. Forte (investors) James S. Scibetta (investors)

(617) 768-6881 (212) 750-6700

Maria E. Cantor (media) Sondra S. Newman (media)

(617) 768-6690 (617) 877-5687

SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

2. Abortion Pill approved by FDA
3. Another injectable contraceptive Pill approved by FDA
4. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
5. New FDA Approved Drug To Treat Migraine
6. Lose Weight With New Wonder Slimming FDA approved Prescription Drug
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. FDA approves Phase 0 trial which tests experimental drugs on humans
9. FDA Approves Contraceptive Ring
10. FDA approves new device to treat womens bleeding disorder
11. FDA Approves New HIV Drug, Viread
Post Your Comments:
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology: